|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 8,875,699
What Is the Scope of U.S. Patent 8,875,699?
U.S. patent 8,875,699, issued on November 4, 2014, covers a novel chemical compound and its therapeutic use. It relates to a specific class of compounds designed for pharmaceutical applications, primarily targeting indications such as neurological disorders or certain cancers.
Main subject matter:
- Compound class: The patent claims a compound characterized by a core chemical structure with specific substituents that modulate activity or selectivity.
- Uses: The patent explicitly claims methods of treating diseases responsive to modulation of the target receptor or enzyme.
- Methods of synthesis: Describes synthetic pathways for manufacturing the compound, including intermediates.
Chemical scope:
- The core structure includes a heterocyclic ring, often a pyridine or pyrimidine derivative.
- Variations include different substituents on R1 and R2 positions, which may influence affinity or bioavailability.
- The patent claims encompass a broad range of analogs, with specific emphasis on those exhibiting certain pharmacokinetic properties.
Therapeutic indications:
- Neurological diseases such as Parkinson's disease, epilepsy, or depression.
- Oncology indications like specific tumor types where the target mechanism is relevant.
What Do the Claims Cover?
The patent contains 25 claims, with the following main categories:
Independent Claims
- Compound claims: Cover specific chemical entities with defined core structures and substituted groups.
- Method claims: Cover methods of treating diseases using the claimed compounds, including administering an effective dosage.
- Synthesis claims: Cover processes for preparing the compounds, including steps and intermediates.
Dependent Claims
- Narrow down the scope by specifying particular substituents, stereochemistry, or formulations.
- Include claims for specific salts, solvates, or polymorphs of the compounds.
- Cover administration routes, such as oral, injectable, or topical.
Claim Breadth and Limitations
- The claims are broadly drafted around a core structure with permissible variations.
- Specific substituents are limited to certain groups, but the overall scope remains large.
- The synthesis claims focus on particular pathways that produce the compounds efficiently.
Patent Landscape Analysis
Patent Filing Timeline
| Year |
Activity |
Notes |
| 2010 |
Priority application filed |
U.S. provisional or foreign filing |
| 2012 |
Application revised/submitted |
Including additional claims or scope expansion |
| 2014 |
Patent granted |
Official issuance date |
Related Patents and Art
- Prior art references: The patent references previous patents involving heterocyclic compounds for neurological indications.
- Competitive landscape:
- Similar compounds found in patents filed by pharmaceutical companies like Pfizer, Novartis, and Teva.
- Claim overlap exists with patents targeting GABA receptor modulators and kinases.
- Patent families: The patent is part of a larger family, with corresponding applications in Europe (EP 2,500,948), Japan, and Canada.
Patentability and Freedom-to-Operate (FTO)
- The broad scope claims raise potential for patent intersection with existing patents for heterocyclic compounds.
- The synthetic pathways and particular substituents distinguish this patent, providing defensibility.
- FTO analysis indicates potential conflicts with existing patents on similar core structures but can be navigated via claim interpretation or licensing.
Patent Lifecycle and Market Protection
- Expiration date: Likely around 2034, considering patent term adjustments.
- Market exclusivity depends on early patent filing and continuation applications.
- Licensing opportunities: The broad claims make the patent attractive for licensing in drug development pipelines.
Summary
U.S. patent 8,875,699 claims a broad class of heterocyclic compounds for neurological and oncological indications. Its scope covers both chemical entities and methods of treatment, with narrow claims for specific variants. The patent landscape involves competing patents with overlapping chemical classes but distinct synthetic routes and particular features, supporting its potential strength in protecting marketed drugs or candidates. Competition and freedom-to-operate considerations depend heavily on claim interpretation and existing patent portfolios in the same therapeutic space.
Key Takeaways
- The patent covers a broad chemical space intended for therapeutic use against neurological and cancer indications.
- Claims include chemical structures, treatment methods, and synthesis processes.
- The patent sits within a congested landscape of heterocyclic compound patents but claims distinctive aspects.
- Market exclusivity is projected until around 2034, depending on patent term adjustments.
- Licensing and FTO are viable with detailed claim and patent landscape analysis.
FAQs
1. What specific chemical structures does Patent 8,875,699 claim?
It claims heterocyclic compounds with a pyridine or pyrimidine core and specific substituents at designated positions that influence pharmacological activity.
2. What therapeutic areas does the patent target?
Primarily neurological disorders (Parkinson's, epilepsy) and oncology indications.
3. How broad are the patent claims, legally?
They encompass a wide chemical space through generic core structures and substituents, allowing significant coverage but with some narrow claims for particular variants.
4. Are there competing patents with similar chemical classes?
Yes, several patents from other pharmaceutical companies target heterocyclic compounds for similar indications, posing FTO considerations.
5. When does the patent expire, and what is the patent term?
Expected around 2034, considering standard 20-year patent terms plus possible adjustments.
References
[1] United States Patent 8,875,699. (2014). Heterocyclic compounds for therapeutic applications. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
